natgillin/translations-raw huggingface dataset:
An antibody or binding fragment thereof for use according to claim 1, wherein the inflammatory or thrombotic condition or disorder is at least one or more selected from the group consisting of: vasoocclusive sickle cell pain crisis, thrombosis, atherosclerosis, tumor metastasis, allergic reactions, thyroiditis, psoriasis, dermatitis, nephritis, lupus erythematosis, scleroderma, sepsis, rhinitis, anaphylaxis, diabetes, multiple sclerosis, graft rejection, graft vs. host disease, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, arthritis, and ischemic reperfusion injury, conditions associated with extensive trauma, or chronic inflammation, systematic inflammatory response syndrome, and multiple organ failure. 
Protutijelo ili njegov vežući fragment za uporabu prema zahtjevu 1, naznačen/o time, da je upalno ili trombotičko stanje 1li poremećaj najmanje jedno/jedan ili više odabranih iz skupine koju čine: kriza bolova vazookluzivne srpaste stanice, tromboza, ateroskleroza, tumorske metastaze, elergijske reakcije, tiroiditis, psorijaza, dermatitis, nefritis, lupus eritematoza, skleroderma, sepsa, rinitis, anafilaksa, dijabetes, multipla skleroza, odbijanje alogenskog presatka, bolest - presadak protiv domaćina, astma, kronična opstrukcijska plućna bolest, upalna bolest crijeva, artritis 1 ishemijska reperfuzijska ozljeda, stanja povezana s ekstenzivnom traumom ili kronično zapaljenje, sindrom sustavne upalne reakcije te sindrom višestrukog zastoja organa.
Typically, the hydrogel of the invention is suitable for the treatment of stress or reflex urinary incontinence. 
Tipično je za hidrogel iz ovog izuma da je on prikladan za liječenje stresne ili refleksne urinarne inkontinencije.
In some embodiments, compounds of the present invention are of Formula (Is) wherein X is O (an oxygen atom). 
U nekim oblicima, spojevi prikazanog izuma su Formule (Is) gdje X je O (atom kisika).
The process of the invention preferably occurs in the presence of an organic solvent, more preferably an aprotic organic solvent. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je navedeno organsko otapalo neprotonsko.
The method of claim 1, wherein step c) is performed using a medium containing dexamethason, B-glycerol phosphate, ascorbic acid and bone morphogenic protein (BMP). 
Postupak sukladno zahtjevu 1, pri čemu je korak c) izveden pomoću medija koji sadrži deksametazon, ß-glicerol fosfat, askorbinsku kiselinu i koštani morfogeni protein (BMP).
is selected from hydrogen, methyl, F or Cl; 
R* je izabran od vodika, F ili CI;
The formulation of any of claims 1 to 3, wherein the polypeptide has a solubility of at least 20 mg/mL, preferably 50 mg/mL or more, more preferably 90 mg/mL, as determined by the PEG exclusion method or by a concentration experiment; 
Formulacija prema bilo kojem od zahtjeva 1 do 3, naznačena time što - polipeptid ima topljivost od najmanje 20 mg/mL, poželjno 50 mg/mL ili više, poželjnije 90 mg/mL ili više ili 120 mg/mL, ili više, najpoželjnije 150 mg/mL ili više, ili čak 200 mg/mL, ili više, kako je određeno PEG postupkom isključivanja ili pokusom koncentracije;
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES and which does not bind to CCL2/MCP-1, comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) selected from the group consisting of SEQ ID NOS: 33/34/35/38/39/40 and 63/64/65/68/69/70, or which competes for binding to CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination selected from the group consisting of SEQ ID NOS: 33/34/35/38/39/40 and 63/64/65/68/69/70. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na CCL3/MIP-1a, CCL4/MIP-1B, i CCL5/RANTES i koji se ne veže na CCL2/MCP-1, koji obuhvaća kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) odabranih iz skupine koja se sastoji od SEQ ID NOS: 33/34/35/38/39/40 i 63/64/65/68/69/70, ili koji se natječe za vezanje na CCL3/MIP-1a, CCL4/MIP-1B, i CCL5/RANTES, s antitijelom ili fragmentom koji veže antigen i sadrži kombinacije CDR nizova teških i lakih lanaca odabrane iz skupine koju čine CEQ ID NO: 33/34/35/38/39/40 i 63/64/65/68/69/70.
a monoclonal antibody comprising a light chain variable domain containing residues 46-52, 70-72 and 111-116 of SEQ ID NO:2; 
(i) monoklonalnog antitijela koje sadrži varijabilno područje lakog lanca koje sadrži ostatke 46-52, 70-72 i 111-116 od SEQ ID br. 2;
The solid dosage form of claim 10, wherein the solid dosage form takes the form of a bilayer tablet having the flurbiprofen or pharmaceutically acceptable salts thereof in one layer and an a-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist in another layer. 
Čvrsti dozni oblik prema zahtjevu 10, naznačen time što je rečeni čvrsti dozni oblik formuliran kao dvoslojna tableta koja sadrži flurbiprofen ili njegovu farmaceutski prihvatljivu sol u jednom sloju, a agonist a-2 adrenergičkog receptora, ili agonist gama-aminobutanske kiseline u drugom sloju.
calculating a sequence number using a hopping pattern that defines a variation of sequence numbers over time, the sequence number being calculated differently by whether a CoMP, Coordinated Multiple Point transmission and reception, mode or Non-CoMP mode is set, wherein, when the CoMP mode is set, a plurality of base stations or cells communicate with the radio communication apparatus in a coordinated manner between the plurality of base stations or cells; generating a sequence used for a reference signal using the calculated sequence number; and transmitting the reference signal using the generated sequence. 
referiranje na pluralitet različitih obrazaca skoka imajući prvi obrazac skoka i drugi obrazac skoka za skakanje brojem Zadoff-Chu, ZC, sekvence koji se koristi za referentni signal i izračun broja sekvence ZC koristeći jedan od pluraliteta obrazaca skoka, prvi obrazac skoka koristeći se kad je CoMP način rada postavljen, i drugi obrazac skoka koristeći se kad je način rada ne-CoMP postavljen; i generiranje ZC sekvence koja se koristi za referentni signal koristeći izračunat broj ZC sekvence.
A process for preparing a trans-amino acid derivative of formula 1, the process comprising reacting a mixture of lactams of formula IV and formula V, with a base in the presence of an alcohol. 
Postupak dobivanja trans-aminokiselinskog derivata formule I [image] naznačen time što se navedeni postupak sastoji u reakciji smjese laktama formule IV i formule V [image] s bazom, u prisutnosti alkohola.
A metering device 6 is used to dispense the additive into the line 2. 
Dozator 6 se koristi za ispuštanje aditiva u cjevovod 2.
The pharmaceutical composition of claim 9, further comprising a nucleoside analogue. 
Farmaceutski sastav patentnog zahtjeva 8, gdje je inhibitor NS5B polimeraze nukleotidni inhibitor. sena mnE
The antibody, or antigen-binding portion thereof, of any one of claims 1-8, wherein said antibody is a hypofucosylated antibody. 
Antitijelo, ili njegov antigen-vezujući dio, iz bilo kojeg od Zahtjeva 1-8, naznačeni time, što je spomenuto antitijelo hipofukozilirano antitijelo.
A method for making a cell that expresses an antibody comprising a human λ variable domain, comprising the steps of: exposing a genetically modified mouse to an antigen, wherein the genetically modified mouse has a genome comprises an immunoglobulin locus comprising human Vλ and Jλ gene segments operably linked to a mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable domain derived from the Vλ and Jλ gene segments fused with a mouse k constant domain; 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
Water soluble salts of ascorbic acid may be administered parenterally or subcutaneously. 
Soli askorbinske kiseline topive u vodi mogu se davati parenteralno ili supkutano.
a fuel gas supply line connected from the LNG tank to the high-pressure gas injection engine of the vessel, 
vod za dobavu pogonskog plina spojen iz spremnika LNG (1) do visokotlačnog plinskog injekcijskog motora za brod;
A method of assembling and pressure testing a gas valve unit (10) for a gas consumer in a marine vessel, the method comprising: 
Postupak za sastavljanje 1 tlačno ispitivanje jedinice plinskog ventila (10) za potrošača plina u morskom plovilu, naznačen time što postupak obuhvaća:
A maize plant cell, tissue or plant comprising a chimeric transcription regulatory region comprising one or more copies of the sugarcane bacilliform viral (SCBV) enhancer element shown in position 337 to position 618 of SEQ ID NO: 1, or a homolog thereof having at least 90% identity to position 337 to position 618 of SEQ ID NO: 1; and operably linked thereto a heterologous promoter comprising an RNA polymerase binding site and a mRNA initiation site, in which the chimeric transcription regulatory region is inserted into a genome of the maize plant cell, tissue or plant at a random location. 
Biljna stanica kukuruza, tkivo ili biljka kukuruza, naznačena time, da obuhvaća kimerno regulacijsko područje transkripcije koje obuhvaća jednu ili više kopija elemenata pojačivača virusa šećerne trske bacilnog oblika (SCBV- pojačivača) prikazanog na poziciji 337 do pozicije 618 od SEQ ID NO: I, ili njegov homolog koji ima najmanje 90% identiteta s pozicijom 337 do pozicije 618 od SEQ ID NO: I; 1 s time operativno povezan jedan heterologni promotor koji obuhvaća mjesto vezanja RNK polimeraze i mjesto inicijacije mRNK, gdje se kimerno regulacijsko područje transkripcije uvodi u genom biljne stanice kukuruza, tkivo ili biljku kukuruza na nasumičnim mjestima.
The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein b is 0. 
Spoj ili sol za upotrebu prema zahtjevu 6, pri čemu b je 0.
According to one particular embodiment, the process further comprises a step f) of stopping the crosslinking that consists in exposing the crosslinked gel to conditions conducive to stopping its crosslinking, this step possibly being carried out prior to, together with or subsequent to the recovery step e). 
Postupak prema zahtjevu 1, naznačen time da nadalje sadrži korak f) zaustavljanja umrežavanja, navedeni korak f) se provodi prije, zajedno s ili nakon koraka obnavljanja €).
Since controlled-release dosage forms containing active ingredients with abuse potential do not give rise to the kick desired by the abuser when taken orally even in abusively high quantities, such dosage forms are also comminuted and extracted in order to be abused. U.S. Pat. No. 4,070,494 proposed adding a swellable agent to the dosage form in order to prevent abuse. 
Budući da oralni oblici davanja za produženo oslobađanje koji sadrže djelatne tvari s potencijalom zlouporabe, čak kod uobičajenog oralnog uzimanja zlouporabno velikih količina ne dovode do užitka koji želi zlorabitelj, ovi se za zlouporabu također usitnjuju i ekstrahiraju. Za sprečavanje zlouporabe u US-i4-4,070,494 je predloženo, da se obliku davanja lijeka doda sredstvo za bubrenje.
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 
7. = Farmaceutski pripravak, naznačen time, da sadrži spoj sukladno bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljivi nosač ili otapalo.
A slide according to claim 1 and it is characterized in that it comprises at least one slowing down counter flow nozzle (13) in each sliding lane (14.1, 14.2) providing opposite direction flowing of water in order to decrease the speed towards end of the said sliding lanes (14.1, 14.2). 
Tobogan sukladno zahtjevu 1 naznačen time što barem jednu mlaznicu suprotnog tijeka za usporavanje (13) u svakoj traci za spuštanje (14.1, 14.2) koja pruža suprotni smjer (14.1, 14.2).
LDPC-encoding the BCH-encoded Layer 1 signaling data to generate LDPC parity bits; 
LDPC-kodiranje BCH-kodiranih signalnih podataka L1 zbog stvaranja LDPC paritetnih bitova;
The method of claim 1, wherein the cumulative total amount of glutamate per unit volume in said medium is less than 1 mM. 
Postupak prema Zahtjevu 1, što je kumulativna ukupna količina glutamata po jedinici volumena u spomenutom mediju manja od približno 1 mM.
As a result of this combination the present invention relates to an antibody or antigen-binding fragment thereof for use in the treatment of certain groups of subjects by certain dosage regimens. 
HR (54) Naziv izuma: LJUDSKA PROTUTIJELA ZA PCSK9 ZA UPORABU U POSTUPCIMA LIJEČENJA ODREĐENIH SKUPINA SUBJEKATA
with a compound selected from the salt compounds of Formulae Id and Id', in the presence of at least one peptide coupling reagent and at least one reagent having a basic nitrogen atom selected from a tertiary amine, a tertiary amide, a morpholine compound and mixtures of two or more thereof; and when the salt compound selected in Step (iv) is a compound of Formula Id', oxidizing the compound Ic produced in Step (iv) to yield the compound of Formula I. 
Formula id' u prisutnosti barem jednog reagensa za spajanje peptida i barem jednog reagensa koji ima bazni dušikov atom, izabranog između tercijarnog amina, tercijarnog amida, spoja morfolina te mješavina dvaju ili tri od njih; 1 (v) ako je spoj soli izabran u koraku (iv) spoj Formule Id", oksidacija spoja Ic dobivenog u koraku (iv) da se dobije spoj Formule I.
The composition of claim 1, wherein phosphate is present in an amount of 1% or less by weight. 
Smjesa prema zahtjevu 1, gdje je fosfat prisutan u količini od 1% ili manje, težinski.
RB6 is F or C1-2alkyl, or two RB6 and an intervening carbon atom from a spirocyclopropyl or spirocyclobutyl ring. 
R5 je Fili Cpoalkil, ili dva R%* i intervenirajući atom ugljika tvore spirociklopropilni ili spirociklobutilni prsten; ili b) Prsten B je
A compound according to claim 1, wherein R2 and R′2, together with the nitrogen atom to which they are linked, form a thiomorpholinyl group. 
Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time da R2 1 R',, zajedno sa atomom dušika na koji su spojeni, formiraju tiomorfolinilnu skupinu.
The method of any one of the preceding claims, wherein said control biological sample is obtained from said subject up to three years preceding diagnosis. 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, što se navedeni kontrolni biološki uzorak uzima od navedenog subjekta do tri godine prije dijagnoze.
A container according to claim 8, wherein the at least one indicium (127) is formed by at least one indicium cut out in the inner frame, such that the inner package is visible through the at least one indicium cut out. 
Ambalaža prema zahtjevu 9, naznačena time što se najmanje jedna oznaka (127) formira bar jednim isječkom u unutarnjem okviru, tako da se unutarnje pakiranje vidi kroz bar jedan isječak s oznakom.
The solid support of claim 1, wherein the solid support comprises a patterned surface or an array of wells. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što čvrsti nosač uključuje mikročestice, ili površinu s uzorkom, ili jažice.
The image processing apparatus according to any of claims 1 to 3, wherein the image processing apparatus performs image processing so as the isotropic blur image and the anisotropic blur image to be subtracted less largely from the band image as the edge reliability corresponding to the pixel to be processed becomes lower. 
Uređaj za obradu slike prema bilo kojem od zahtjeva 1 do 3, naznačen time, da uređaj za obradu slike izvodi obrađivanje slike tako, što se izotropna zamagljena slika (P1) i neizotropna zamagljena slika (P2) trebaju odbiti iz slike na traci (a, B, Y) manje opsežno, kako pouzdanost rubova (E) odgovarajuća za piksel koji se treba obraditi, postaje manja.
The plates have generally planar surfaces, wherein a multiplicity of recurring groove structures 4 which form flow channels are disposed in a surface of at least one of the plates, which is joined to the surface of the other plate. 
Ploče imaju općenito ravne površine, pri čemu je više ponavljajućih brazdastih struktura 4, koje tvore protočne kanale, raspoređeno u površini najmanje jedne ploče, koja je spojena s površinom druge ploče.
In yet another embodiment the present invention relates to a mucosal bioadhesive slow release carrier comprising a wetting agent comprising 10 to 200 mg of an antiviral agent selected from the group of acyclovir, valacyclovir, gancyclovir and zidovudine, 1 to 75% by weight of a diluent of microcrystalline cellulose and 2 to 10% by weight of sodium lauryl sulphate and further comprising 0.5 to 5% by weight of a polyvinylpyrrolidine and 10 to 40% by weight of at least one bioadhesive polymer selected from the group of natural milk proteins and mixtures thereof and 10% to 40% by weight of hypromellose. 
Nosač bioadhezivan za sluznicu sa sporim oslobađanjem koji se može dobiti pomoću postupka prema patentnom zahtjevu 1, naznačen time što sadrži 10 do 200 mg antivirusnog sredstva koji je izabran iz grupe koju čine aciklovir, valaciklovir, ganciklovir i zidovudin, 1 do 75 težinskih % mikrokristalne celuloze, 2 do 10 težinskih % natrij lauril sulfata i 0.5 do 5 težinskih % polivinilpirolidona i 10 do 40 težinskih % najmanje jednog bioadhezivnog polimera koji je izabran iz grupe koju čine prirodni proteini mlijeka i njihove smjese i 10% do 40 težinskih % hipromeloze. .
is hydrogen, C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C1-6 alkyl) or an optionally substituted C-amido; 
R? je vodik, C,4 alkil, po izboru supstituiran C3.4 cikloalkil, po izboru supstituiran aril, po izboru supstituiran ari KC, 4 alkil) ili po izboru supstituiran C-amido;
Obtained product was re-purified on a preparative HPLC column (80% methanol- 20% water, flow 10mL/min.), yielding 1.461g of 42-O-(D-fructosylcarbonyl)rapamycin as white solid (freeze dried from benzene). 
Dobiveni produkt ponovno je pročišćen na preparativnoj HPLC koloni (80% metanol - 20% voda, protok 10 mL/min), i daje 1,461 g 42-OÂ«(D-fruktozilkarbonil)rapamicina kao bijelu krutinu (osušeno smrzavanjem iz benzena).
Compounds of the invention may conveniently be administered in amounts of, for example, 0.01 to 100mg/kg body weight, preferably 0.1 to 25 mg/kg body weight, more preferably 0.3 to 5mg/kg body weight. 
Spojevi prema ovom izumu može se pogodno primijeniti u količinama od, primjerice, 0,01 do 100 mg/kg tjelesne težine, po mogućnosti 0,1 do 25 mg/kg tjelesne težine, poželjnije 0,3 do 5 mg/kg tjelesne težine.
A method according to any one of claims 6-13 wherein the compound of formula (II) is formed by a method comprising the step of reacting a compound of formula (I) with less than a molar equivalent of a compound of formula (V) wherein R5 is C1-5 alkyl. 
Postupak koji se odnosi na bilo koji od patentnih zahtjeva 6-13 pri čemu se spoj formule (II) stvara u postupku koji podrazumjeva korak reakcije spoja formule (I) s manje od molarnog ekvivalenta spoja formule (V) R! A
each Het3 is a heterocyclic radical selected from 1,3-thiazolyl optionally substituted with C1-3alkyl; unsubstituted benzofuranyl; unsubstituted 3,4-dihydro-2H-chromenyl; and unsubstituted 1H-indolyl; 
svaki Het3 je heterociklički radikal izabran od 1,3-tiazolila po izboru supstituiran s C1-3alkil; nesupstituirani benzofuranil; nesupstituirani 3,4-dihidro-2H-kromenil; i nesupstituirani 1H-indolil;
The method as in embodiment 11, wherein the liquid substance is water based. 
Postupak prema zahtjevu 10, naznačen time što je tekuća supstanca bazirana na vodi i sadrži glikol ili glicerin.
The compound of Claim 1 wherein the compound is a compound of formula (IV): wherein: 
Spoj u skladu s patentnim zahtjevom 1, da je spoj, spoj formule (IV): [image] naznačen time, da:
Device for biological treatment and post-treatment of wastewater according to claim 1 wherein a common aperture serves as both inlet (26) and outlet (77) for draining wastewater and sludge from back-flushing of the sedimentation zone (33) and the filtration zone (35). 
Uređaj za biološku obradu i naknadno pročišćavanje otpadne vode sukladno patentnom zahtjevu 1, naznačeno time da, zajednički otvor služi kao 1 ulazni otvor (26) i izlazni otvor (77) za ispuštanje otpadne vode i mulja iz povratnog ispiranja iz zone sedimentacije (33) i zone filtriranja (35).
Pharmaceutical composition according to any one of claims 1 or 3 to 15 in the form of a tablet. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 1li 3 do 15, naznačen time, da je u obliku tablete.
Following oral administration of ST1469, the plasma concentrations of the molecule increase until they reach the maximum concentration (Cmax) of approximately 280 pmol/mL, two hours after administration. 
Nakon oralne primjene ST1469, plazma koncentracije molekule s povisuju dok ne dosegnu maksimalnu koncentraciju (Cmax) Od otprilike 280 pmol/ml, 2 sata nakon primjene.
Example 3: Selection of the New Hybrids 
Broj objave europskog patenta:
The method of claim 5, wherein the removable cap includes a clip affixed to a rear portion of the removable cap, and further comprising clipping the air freshener device onto a vent in an automobile climate system. A method to release fragrance from a scented material, the method comprising: 
Postupak prema zahtjevu 5, naznačen time, da premjestiva kapica (112) obuhvaća kvačicu (110) koja je pričvršćena na stražnji dio premjestive kapice, i postupak dodatno obuhvaća zakvačenje uređaja za osvježivanje zraka na otvor za ventilaciju u automobilskom sustavu klimatizacije.
cycloalkylene with 5 to 7 carbon atoms into cycloalkylene ring, the ring being optionally substituted with side chains T1, wherein T1 is straight or branched C1-C10 alkyl, preferably CH3; 
- cikloalkilen s 5 do 7 ugljikovih atoma u cikloalkilenskom prstenu, a prsten može biti supstituiran s bočnim lancima Ti, gdje je T; ravni ili razgranati Ci-Croalkil, b)
An absorbent sheet (10) of cellulosic fibers with upper and lower sides, the absorbent sheet (10) characterized by: 
PATENTNI ZAHTJEVI Apsorbirajuća ploha (10) od celuloznih vlakana s gornjom 1 donjom stranom, apsorbirajuća ploha (10) karakterizirana:
A sterile package comprising the baked composition of any one of claims 1 to 4 or 6 to 13. 
Sterilno pakiranje koje sadrži pekarsku kompoziciju iz bilo kojeg od patentnih zahtjeva 1 do 4ili 6 do 13.
The antibody according to claim 1, characterized in that it is a full length IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibody. 
Protutijelo sukladno patentnom zahtjevu 1, karakterizirano time da je u punoj duljini IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, ili IgM protutijelo.
The thieno[3,2-d]pyrimidine derivative of claim 1, wherein Z is NR3R4 or a pharmaceutically acceptable salt thereof. 
Derivat tieno[3,2-d]pirimidina u skladu s patentnim zahtjevom 1, pri čemu Z je NRŽR* ili njegova farmaceutski prihvatljiva sol.
The pharmacokinetic profiles of gemcitabine and a compound of formula I, are assessed in cynomolgus monkeys following oral and intravenous administration in a crossover design. 
Farmakokinetički profili gemcitabina i spoja formule I procijenjeni su na cinomolgus majmunima nakon oralne i intravenske primjene na ukriženi način.
The compound of claim 9 or 11, or a pharmaceutically acceptable salt thereof, wherein R23 is C1-C6 alkoxy. 
12. Tvar iz patentnog zahtjeva 9 ili 11, ili njena farmaceutski prihvatljiva sol, pri čemu je R23 Ci-Cg alkoksi.
The use according to claim 1, where dose a is within the range of from 10 to 90 wt.-% of dose b. 
Lijek prema patentnom zahtjevu 8, naznačen time da je doza a unutar raspona od 10 do 90 % po težini doze b.